Cytomegalo-immunoglobulin for intramuscular use. First experiences on bioavailability.
Results are given on tolerability and bioavailability of an intramuscular immunoglobulin (Ig) preparation (BI 2.011) with high titer against cytomegalo-virus (CMV). For rapid and long-lasting protection a dosage of 0.2 ml/kg body weight anti-CMV-Ig with a titer of 1:50 000 (Enzyme-Linked Immunosorbent Assay) is recommended. Prophylaxis should be taken into account in seronegative patients suffering from immune defects, that experience transplantation surgery and/or multiple injections of blood products.
D000328:Adult; D000914:Antibodies, Viral / Q000008:administration & dosage*; D001682:Biological Availability; D003587:Cytomegalovirus / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D000914:Antibodies, Viral; D007074:Immunoglobulin G